RxDoctor Payments Data

Michele Miller, NP

Psychiatric/Mental Health · Philadelphia, PANPI 1679876494

Payments from drug & device makers

$1,481in general payments, 2019–2025

Across 81 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$532
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$218
  • Vanda Pharmaceuticals Inc.$142
  • Alkermes, Inc.$136
  • Johnson & Johnson$114
  • Teva Pharmaceuticals USA, Inc.$109
  • plus $229 from 6 others

What the payments were for

  • Food & beverage$1,45698%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,481 in reported general payments places this provider in the 70th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,130
Medicare patients
18
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl41$56,322
RexultiBrexpiprazole27$43,619
Abilify MaintenaAripiprazole15$36,440
CaplytaLumateperone Tosylate11$17,626
TrintellixVortioxetine Hydrobromide29$14,409
Lurasidone Hcl19$7,254
Varenicline Tartrate11$5,064
Bupropion XlBupropion Hcl107$2,819
Duloxetine Hcl78$1,943
Aripiprazole45$1,742
Quetiapine Fumarate132$1,684
Fluphenazine Decanoate14$1,642
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine28$1,285
Doxepin Hcl52$1,108
Clonazepam117$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$48$80,05942 claims
AbbVieVraylar$532$56,32241 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$218$17,62611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$97$14,40929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →